https://www.selleckchem.com/products/ars-853.html
Over a median follow-up of 5years, five of the 93 patients (5.4%) developed structural neck recurrence on US at a median of 2.5years after initial treatment. Indeterminate US abnormalities were detected in 19 of the 93 patients (20.4%) leading to additional tests, which did not detect significant disease. In ATA low-intermediate-risk PTC with no suspicious findings on neck US and a non-stimulated thyroglobulin of 1.0ng/mL after initial therapy, frequent US is more likely to identify non-actionable abnormalities than clinically signi